THSD1 (thrombospondin type-1 domain-containing protein 1) is a transmembrane glycoprotein implicated in vascular biology, cell adhesion, and angiogenesis. It interacts with integrins and extracellular matrix components, playing roles in endothelial cell signaling, vascular stability, and platelet function. THSD1 is expressed in various tissues, including the brain, placenta, and blood vessels. Research links it to neurological and cardiovascular disorders, such as cerebral cavernous malformations and preeclampsia, due to its involvement in maintaining vascular integrity.
THSD1 antibodies are essential tools for studying the protein's expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect THSD1 in biological samples. Commercially available antibodies are typically raised in rabbits or mice using peptide antigens derived from conserved regions of human THSD1. Validation includes testing for specificity via knockout controls or siRNA knockdown.
Recent studies highlight THSD1's potential as a therapeutic target, particularly in diseases involving aberrant angiogenesis or vascular leakage. However, its precise mechanisms remain under investigation. Researchers rely on THSD1 antibodies to explore its interactions with signaling pathways (e.g., PI3K/Akt) and its role in pathological conditions. Continued development of high-affinity, validated antibodies is critical for advancing understanding of THSD1 in health and disease.